Mural Oncology

Mural Oncology company information, Employees & Contact Information

Explore related pages

Related company profiles:

We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients’ lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)
Looking for a particular Mural Oncology employee's phone or email?

Mural Oncology Questions

News

Mural Oncology Shareholders Approve Acquisition by XRA 5 Corp, a Subsidiary of XOMA Royalty Corporation - Quiver Quantitative

Mural Oncology Shareholders Approve Acquisition by XRA 5 Corp, a Subsidiary of XOMA Royalty Corporation Quiver Quantitative

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - GlobeNewswire

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share GlobeNewswire

Xoma adds fading Mural Oncology to portfolio of struggling biotechs - Fierce Biotech

Xoma adds fading Mural Oncology to portfolio of struggling biotechs Fierce Biotech

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction - Pharmaceutical Executive

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction Pharmaceutical Executive

Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Clinical Trials Arena

Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% Clinical Trials Arena

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech - BioPharma Dive

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech BioPharma Dive

Mural Oncology plc Publishes Definitive Proxy Statement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative

Mural Oncology plc Publishes Definitive Proxy Statement for Acquisition by XOMA Royalty Corporation Quiver Quantitative

XOMA buys third biotech this month, as it swoops up Mural Oncology - Endpoints News

XOMA buys third biotech this month, as it swoops up Mural Oncology Endpoints News

Mural Oncology (MURA) Q2 Loss Widens 49% - The Motley Fool

Mural Oncology (MURA) Q2 Loss Widens 49% The Motley Fool

Mural Oncology To Be Acquired By XOMA Royalty - Stocktwits

Mural Oncology To Be Acquired By XOMA Royalty Stocktwits

Spin-Off Research Slashes Mural Oncology Valuation - Forbes

Spin-Off Research Slashes Mural Oncology Valuation Forbes

Mural Oncology Slashes Workforce by 90%, Explores Sale with $77M Cash Runway - Stock Titan

Mural Oncology Slashes Workforce by 90%, Explores Sale with $77M Cash Runway Stock Titan

Massachusetts biotech company cuts 90% of its workforce - NBC Boston

Massachusetts biotech company cuts 90% of its workforce NBC Boston

Biotech downturn claims another victim with sweeping Mural Oncology layoffs - Talent24h

Biotech downturn claims another victim with sweeping Mural Oncology layoffs Talent24h

Failed Cancer Trial Forces Mural Oncology to Halt Development and Cut 90% of Workforce - Stock Titan

Failed Cancer Trial Forces Mural Oncology to Halt Development and Cut 90% of Workforce Stock Titan

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives - Fierce Biotech

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives Fierce Biotech

Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study - Stock Titan

Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study Stock Titan

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth? - Yahoo Finance

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth? Yahoo Finance

Citadel Group discloses 1.34% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.34% stake in Mural Oncology Investing.com

Citadel Group discloses 1.35% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.35% stake in Mural Oncology Investing.com

Citadel Group discloses 1.32% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.32% stake in Mural Oncology Investing.com

Citadel Group discloses 1.32% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.32% stake in Mural Oncology Investing.com

Mural Oncology Appoints George Golumbeski, Ph.D., to its Board of Directors - citybiz

Mural Oncology Appoints George Golumbeski, Ph.D., to its Board of Directors citybiz

Citadel Group discloses 1.73% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.73% stake in Mural Oncology Investing.com

Citadel Group discloses 1.76% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.76% stake in Mural Oncology Investing.com

BlackRock discloses 1.61% stake in Mural Oncology - Investing.com

BlackRock discloses 1.61% stake in Mural Oncology Investing.com

After culling 90% of staff, Waltham biotech finds buyer - NBC Boston

After culling 90% of staff, Waltham biotech finds buyer NBC Boston

Citadel Group discloses 1.33% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.33% stake in Mural Oncology Investing.com

Citadel Group discloses 1.75% stake in Mural Oncology - Investing.com

Citadel Group discloses 1.75% stake in Mural Oncology Investing.com

Mural Oncology accepts XOMA takeover bid - The Pharma Letter

Mural Oncology accepts XOMA takeover bid The Pharma Letter

Trium Capital discloses 10.86% stake in Mural Oncology - Investing.com

Trium Capital discloses 10.86% stake in Mural Oncology Investing.com

Mural Oncology Ends Nemvaleukin Program, Begins Strategic Review - Nasdaq

Mural Oncology Ends Nemvaleukin Program, Begins Strategic Review Nasdaq

BlackRock discloses 1.65% stake in Mural Oncology - Investing.com

BlackRock discloses 1.65% stake in Mural Oncology Investing.com

Mural Oncology plc Opening Position Disclosure Under Irish Takeover Rules - Nasdaq

Mural Oncology plc Opening Position Disclosure Under Irish Takeover Rules Nasdaq

Boston-area cancer research lab to cease drug trials, lay off 117 - MassLive

Boston-area cancer research lab to cease drug trials, lay off 117 MassLive

Mural Oncology Faces Critical Tests: What’s Next? - StocksToTrade

Mural Oncology Faces Critical Tests: What’s Next? StocksToTrade

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies - Stock Titan

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies Stock Titan

Caroline J Loew: We’re excited to launch Mural Oncology - Oncodaily

Caroline J Loew: We’re excited to launch Mural Oncology Oncodaily

Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives - Stocktwits

Mural Oncology's Retail Buzz Explodes After Micro-Cap Biotech Mulls Strategic Alternatives Stocktwits

BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com Nigeria

BlackRock discloses stake in Mural Oncology By Investing.com Investing.com Nigeria

MURA - Mural Oncology PLC Latest Stock News & Market Updates - Stock Titan

MURA - Mural Oncology PLC Latest Stock News & Market Updates Stock Titan

MURA Stock Price and Chart — NASDAQ:MURA - TradingView

MURA Stock Price and Chart — NASDAQ:MURA TradingView

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care - Pharma Voice

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care Pharma Voice

Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout - Fierce Biotech

Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout Fierce Biotech

Top Mural Oncology Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant